Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3,4-DAP Withdrawal Study in LEMS
NCT01511978Phase 2Completed
- Sponsor
- Jacobus Pharmaceutical Company Inc.
- Start
- Jan 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Ruzurgi in Lambert-Eaton myasthenic syndrome (LEMS), sponsored by Jacobus Pharmaceutical Company Inc.. Started Jan 2012; status: completed.
02
Drugs
Ruzurgi
03
Conditions
Lambert-Eaton myasthenic syndrome (LEMS)
Beyond the preview
Go deeper on NCT01511978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01511978.